Intellia Q2 net loss $123.7M; advances CRISPR pipeline with Phase 2 enrollment for NTLA-2002 completed

Intellia Therapeutics, Inc.

Cash, equivalents and securities $1.1B at June 30, 2023, down from $1.3B at Dec 31, 2022.
Net loss $123.7M in Q2 2023 vs $100.7M in Q2 2022; R&D expenses rose to $115.3M.
All patients identified for NTLA-2002 Phase 2 study; pivotal Phase 3 planned for Q3 2024.
NTLA-2001 IND submission for ATTR-CM expected in September; global pivotal study targeted by year-end 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Intellia Therapeutics, Inc. reported financial results for the quarter ended June 30, 2023.

Period: the quarter ended June 30, 2023
Result: reported results

Exact text from the filing

On August 3, 2023, Intellia Therapeutics, Inc. announced its financial results and business updates for the quarter ended June 30, 2023.

View on SEC.gov

Browse all earnings releases →

Intellia Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-037597

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.